Physician profile
Phillip Michael Watson
NPI 1598735433
$5,144.40
in general payments reported to CMS, 2019-2025
31 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $698 · 2021: $1,184 · 2022: $853 · 2023: $579 · 2024: $546 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,457.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $798.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $566.29 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $513.82 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $423.79 | 2022-2025 | |
| Abbvie INC. | $420.82 | 2021-2024 | Vraylar |
| Pfizer INC. | $328.92 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.18 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $264.72 | 2019-2021 | |
| Lilly USA, LLC | $249.18 | 2019-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $178.60 | 2019-2021 | |
| Astellas Pharma US INC | $155.98 | 2019-2024 | Veozah |
| Abbott Laboratories | $87.20 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $85.77 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $76.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $67.69 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $67.42 | 2023-2024 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $66.43 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $56.24 | 2020-2022 | |
| Zyla Life Sciences, INC. | $53.72 | 2019 | |
| Phathom Pharmaceuticals, INC. | $52.57 | 2023-2024 | Voquezna |
| Allergan, INC. | $51.51 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.33 | 2022-2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $48.35 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.60 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $38.65 | 2023-2024 | Keveyis, Gvoke Hypopen |
| Amgen INC. | $30.07 | 2019-2020 | |
| Lundbeck LLC | $23.87 | 2024 | Rexulti |
| Daiichi Sankyo INC. | $21.09 | 2020 | |
| Valeritas, INC. | $18.56 | 2019 | |
| Circassia INC. | $13.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.